Skip to main content

Table 3 Incidence of Severe Neutropenia

From: Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy

  RGB-02 Reference Difference(RGB-02 - Reference)
Cycle 1, PP population
 n 117 113  
 n (%) with severe neutropenia 99 (84.6) 87 (77.0)  
 Proportion (95% CI) with severe neutropenia 0.846 (0.768, 0.906) 0.770 (0.681, 0.844) 0.076 (−0.055, 0.204)
Cycle 2, PP population
 n 111 103  
 n (%) with severe neutropenia 60 (54.1) 45 (43.7)  
 Proportion (95% CI) with severe neutropenia 0.541(0.443, 0.636) 0.437(0.339, 0.538) 0.104(−0.031, 0.236)